Cost-effectiveness analysis of recombinant factor VIII Fc-fusion protein (rFVIIIFc) for the treatment of severe hemophilia A in Italy incorporating real-world dosing and joint health data

Bullement, A. orcid.org/0000-0001-7091-0972, McMordie, S.T., Hatswell, A.J. et al. (2 more authors) (2020) Cost-effectiveness analysis of recombinant factor VIII Fc-fusion protein (rFVIIIFc) for the treatment of severe hemophilia A in Italy incorporating real-world dosing and joint health data. PharmacoEconomics - Open, 4. pp. 133-142. ISSN 2509-4262

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © The Author(s) 2019. Open Access: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Dates:
  • Published (online): 6 July 2019
  • Published: March 2020
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Health and Related Research (Sheffield)
Depositing User: Symplectic Sheffield
Date Deposited: 12 Jan 2021 14:59
Last Modified: 13 Jan 2021 18:21
Status: Published
Publisher: Springer Science and Business Media LLC
Refereed: Yes
Identification Number: https://doi.org/10.1007/s41669-019-0158-8
Related URLs:

Share / Export

Statistics